

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 26 March, 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Board of Directors of Pharma Mar, S.A. (the “**Company**”), which met yesterday, 25 March, resolved to propose for approval at the next General Shareholders' Meeting the distribution of a dividend of 0.80 euros per outstanding share, in recognition of the commitment of our shareholders and reflecting the results obtained.

This proposal underscores the company's financial strength and its commitment to creating sustained value for its shareholders. Once approved by the General Shareholders' Meeting, the dividend will be paid out of unrestricted reserves (share premium) up to a maximum amount of 14,577,782.40 euros. The final amount will be determined at the time of distribution of the dividend, based on the Company's shares in circulation and those held as treasury stock at that time.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

PharmaMar's Board of Directors proposes a 23% increase in the dividend

Madrid, March 26th, 2025.- PharmaMar's Board of Directors (MSE: PHM) announced today that it will submit for approval at the upcoming General Shareholders' Meeting the distribution of a dividend of €0.80 per share in circulation, representing a 23% increase compared to the cash dividend of €0.65 per share paid last year.

This proposal underscores the Company's financial strength and its commitment to creating sustained value for its shareholders. The dividend, which would be paid from unrestricted reserves (share premium), would involve a maximum payout of €14,577,782.40.

The PharmaMar Board of Directors' proposal represents the distribution of a dividend for the sixth consecutive year. During this period, the Company has paid out a total of over €70 million in dividends.

PharmaMar closed the 2024 fiscal year with total revenues of €174.9 million, representing an 11% increase compared to the previous year, and a net profit of €26.1 million, with a net cash position of €109 million at year-end.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns

Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500

